Skip to Content
Merck
  • Synaptic control of DNA methylation involves activity-dependent degradation of DNMT3A1 in the nucleus.

Synaptic control of DNA methylation involves activity-dependent degradation of DNMT3A1 in the nucleus.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2020-07-30)
Gonca Bayraktar, PingAn Yuanxiang, Alessandro D Confettura, Guilherme M Gomes, Syed A Raza, Oliver Stork, Shoji Tajima, Isao Suetake, Anna Karpova, Ferah Yildirim, Michael R Kreutz
ABSTRACT

DNA methylation is a crucial epigenetic mark for activity-dependent gene expression in neurons. Very little is known about how synaptic signals impact promoter methylation in neuronal nuclei. In this study we show that protein levels of the principal de novo DNA-methyltransferase in neurons, DNMT3A1, are tightly controlled by activation of N-methyl-D-aspartate receptors (NMDAR) containing the GluN2A subunit. Interestingly, synaptic NMDARs drive degradation of the methyltransferase in a neddylation-dependent manner. Inhibition of neddylation, the conjugation of the small ubiquitin-like protein NEDD8 to lysine residues, interrupts degradation of DNMT3A1. This results in deficits in promoter methylation of activity-dependent genes, as well as synaptic plasticity and memory formation. In turn, the underlying molecular pathway is triggered by the induction of synaptic plasticity and in response to object location learning. Collectively, the data show that plasticity-relevant signals from GluN2A-containing NMDARs control activity-dependent DNA-methylation involved in memory formation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-MAP2 antibody produced in mouse, clone HM-2, ascites fluid
Sigma-Aldrich
Lactacystin, ≥90% (HPLC)
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
DAPI, dilactate, ≥98% (HPLC)
Sigma-Aldrich
N-Methyl-D-aspartic acid, ≥98% (TLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting human DNMT3A